Background
Head and neck squamous cell carcinoma (HNSCC), which arises in the mucosa of the oral cavity, pharynx and larynx, is the 6th most common cancer worldwide [
1]. Despite advances in available treatments (surgery, radiation, chemotherapy), survival rates at 5 years remain poor. Further, even patients cured by conventional treatment are frequently left with impairments in their abilities to speak, swallow and breathe, as well as facial disfigurements [
2]. The development and clinical implementation of targeted therapeutics is needed to improve the survival outcomes and relieve the toxic burden associated with current HNSCC treatments.
The phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR pathway is a major growth signalling pathway that regulates a variety of cellular processes, including protein and lipid synthesis, proliferation and cell survival [
3]. The PI3K pathway is the most frequently dysregulated pathway in HNSCC, across both HPV-positive and HPV-negative HNSCC tumors [
4‐
6]. Dysregulation of PI3K signalling—stemming from activating mutations or amplifications of
PIK3CA—leads to constitutive activation of the pathway, which can promote tumor development and progression [
5‐
7]. Given the prevalence of PI3K pathway alterations in HNSCC and the role this network plays in tumorigenesis, inhibiting this pathway is a logical therapeutic approach [
7].
Various inhibitors that target one or more of the PI3K isoforms have entered clinical trials [
7]. In fact, the α-isoform specific PI3K inhibitor alpelisib (Piqray®, Novartis) was recently approved by the US Food and Drug Administration (FDA) for treatment of
PIK3CA-mutated, advanced or metastatic breast cancer. To date however, PI3K inhibitors as single agents have generally displayed limited efficacy. These drugs have typically led to cytostasis, rarely inducing tumor cell death or shrinkage [
7,
8]. Moreover, in patients who initially respond to targeted PI3K inhibition, acquired resistance over time has been cited [
9].
Acquired resistance to PI3K inhibition is an area of active research [
9‐
14]. In ovarian cancer, elevated expression of receptor tyrosine kinases (RTKs), including HER2 and EGFR, as well as increased activation of Src, c-Jun and STAT3 have been implicated in mediating resistance to PI3K inhibition by NVP-BEZ235 [
11]. In breast cancer, genetic alterations in
PTEN resulting in loss of expression have been identified in a patient who initially achieved a clinical response to PI3K inhibition before progressing rapidly [
9]. Only a limited number of studies to date have examined acquired resistance to PI3K inhibition in HNSCC. Of these, resistance to the pan-PI3K inhibitor BKM120 has been shown to involve positive feedback activation of IL-6/ERK signalling, while resistance to the α-isoform specific PI3K inhibitor alpelisib has been associated with growth signalling through the PLCγ-PKC network, downstream of the RTK AXL [
12,
15]. It is evident that a number of distinct mechanisms and mediators of resistance to PI3K inhibition exist and may be context-specific according to the drug used and/or cancer type.
As mentioned, alpelisib (formerly BYL719) is an α-isoform specific PI3K inhibitor. It has been shown to exhibit “on-target” PI3K inhibition and anti-cancer efficacy, collectively leading to its recent FDA approval for breast cancer treatment [
7,
8,
16]. Alpelisib targets the p110α catalytic subunit of the Class IA PI3K enzyme encoded by
PIK3CA [
17]. Due to the prevalence of genomic aberrations in
PIK3CA observed in HNSCC, including gain of function mutations and amplifications, alpelisib is a particularly relevant drug. Further, by targeting only the α-isoform, alpelisib has shown to have better tolerability than other, broader-acting PI3K inhibitors, with generally manageable side effects (e.g. hyperglycemia) [
8]. To date, there have been few investigations of how resistance to PI3K inhibition by alpelisib is acquired in the context of HNSCC [
12]. Further, most studies have been limited to in vitro investigations and have not made use of patient-derived xenograft (PDX) models to explore resistance and/or validate their findings [
12,
18].
To capitalize on the promise of PI3K inhibitors in HNSCC, it is essential to understand resistance mechanisms that may be acquired over time; this will enable the design of drug combinations that will be both tolerable and durable [
19]. In the present study, we explored acquired resistance to alpelisib using both HNSCC cell lines and HNSCC PDXs. We observed elevated expression of the AXL RTK, in line with other studies, as well as elevation of its family member TYRO3 in alpelisib-resistant HNSCC models [
12]. Further, we interrogated MAPK pathway activation downstream of AXL and TYRO3 as a critical network for circumventing PI3K inhibition. Collectively our findings emphasize TYRO3 and AXL as key mediators of acquired resistance to PI3K inhibition in HNSCC, through the MAPK pathway. Pan-TAM inhibition may be a promising second-line therapy for HNSCC patients receiving PI3K-targeted agents.
Materials & methods
Cell lines and chemical compounds
Cell lines were obtained from the sources listed (Additional Table
1). We previously used short tandem repeat profiling (The Center for Applied Genetics; Toronto) to confirm cell line identities [
20]. 93-VU-147T cells were cultured in DMEM/F12, with 10% fetal bovine serum (FBS; GIBCO), penicillin (100 IU/mL; Invitrogen) and streptomycin (100 μg/mL; Invitrogen). Cal33 cells were cultured in DMEM, with 10% heat-inactivated FBS, 1x non-essential amino acids (Wisent), penicillin (100 IU/mL) and streptomycin (100 μg/mL). Resistant cell lines were obtained after chronic exposure to increasing concentrations of alpelisib for 3–4 months [
22]. All cells were maintained in a 37 °C humidified atmosphere at 5% CO
2. The inhibitors alpelisib and BI-D1870 were purchased from Selleckchem. Compounds were dissolved in DMSO for in vitro experiments.
Establishment of patient derived xenografts
Mice were handled in accordance with the AUP 1542 approved by the University Health Network Animal Care Committee and in accordance with the CCAC regulations. Xenografts were established and handled as described previously [
21]. Details are provided as
Supplemental Methods & Materials.
Once tumor volumes reached 80-120 mm
3 mice were randomized to either daily (5x/week) alpelisib (Novartis; 50 mg/kg) by oral gavage or a vehicle control (corn oil) [
12,
21]. Individual tumor volumes were calculated using the formula: [length x (width)
2] × 0.52. Where possible, STR profiling was used to confirm matching identities of primary tumors, xenograft tumors, patient blood and PDX-derived cell lines where available (Additional Table
2). Tumors were classified as HPV-positive using immunohistochemistry (IHC) for p16.
Dose response curves
Cells were seeded in 96-well plates at 2400 cells/well and cultured overnight. Drugs were then added over 10-point ranges (0-40 μM). Viability was determined 72 h later using the PrestoBlue® Reagent (Thermo Fisher Scientific) on a Synergy™ H4 Hybrid Reader (BioTek) with 560 nm excitation and 590 nm emission wavelengths. For each dose, viability values were normalized to no-drug controls and average viability for each dose was calculated. To determine the half-maximal inhibitory concentration (IC50) values, normalized relative fluorescence values of drug-treated replicates were calculated as a percentage of the mean RFU of the control replicates and then drug doses were transformed to a logarithmic scale. IC50 values were subsequently calculated by non-linear regression. Values are plotted as mean + standard deviation (SD) using Prism® 7 GraphPad Software.
Clonogenic survival assay
Parental and resistant cell lines were counted and seeded at 500 cells per well into 24-well dishes. Cells were allowed to adhere for 48 h and then were treated with media containing 5 μM alpelisib. For the next 7–14 days, cells were monitored and media replaced every 3 days until visible colonies were formed. Colonies were rinsed with 1x PBS, fixed with cold 100% methanol (MeOH) and stained with 0.5% crystal violet in 25% MeOH/1x PBS. The colonies were then gently washed with water and air-dried. Visible colonies were counted.
Reverse phase protein arrays
Cells were prepared for reverse phase protein arrays (RPPAs) as follows: 10 cm plates were washed twice with cold 1x PBS. Cold lysis buffer (containing: 1% Triton X-100, 50 mM HEPES pH 7.4, 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 100 mM NaF, 10 mM Na pyrophosphate, 1 mM Na3VO4, 10% glycerol and 1% freshly-added protease and phosphatase inhibitors) was added to the plates which were then incubated 20mins on ice with occasional shaking. Lysed cells were centrifuged at 14000 rpm for 10mins at 4 °C. Protein concentration determined by Bradford Assay. Lysates were combined with sample buffer (40% glycerol, 8% SDS, 0.25 M Tris-HCl pH 6.8 and 1/10 volume β-mercaptoethanol –added just before use) at 3 parts lysate:1 part sample buffer. Samples were boiled for 5 mins and stored at − 80 °C.
Samples were submitted to MD Anderson’s Functional Proteomics RPPA Core Facility. Briefly, lysates were serially diluted and arrayed onto nitrocellulose-coated glass slides. Samples were probed with 307 antibodies and visualized by DAB colorimetric reaction. Slides were then scanned and spot densities quantified by Array-Pro Analyzer. All data points were normalized for protein loading and transformed to a linear value. Resistant replicates were then normalized to the mean of their respective parental replicates. Values were then log2-transformed and we restricted our analysis to the top 50% of differentially-expressed proteins for each cell line. Unsupervised hierarchical clustering was performed using the average agglomeration method and Euclidean distance measurements. Clustering was performed in R using the ComplexHeatmap package (version 2.1.1).
Immunoblotting and densitometric analysis
Cell lysates were prepared for immunoblotting as described previously [
23]. A list of primary antibodies used is provided in Additional Table
3. Membranes were visualized following exposure to enhanced chemiluminescence reagent (Luminata™ Crescendo or Luminata™ Forte, Western HRP Substrate; Millipore) on a Bio-Rad ChemiDoc™MP Imaging System.
ImageJ was used to select and determine the background-subtracted density of the bands in all immunoblots. Values were then normalized to their corresponding α-tubulin band. All values are presented below the associated band.
Tissue microarray (TMA) and immunohistochemistry
TMAs were constructed for two of the xenograft models. In brief, the FFPE block for each tumor was sectioned and stained with hematoxylin & eosin (H & E) to confirm the presence of human tumor. Guided by these sections, a Manual Tissue Arrayer (MTA-1; Beecher Instruments Inc.) was used to punch out 3–4 cylindrical cores of 0.6 mm diameter from each sample. Cores were arrayed into recipient paraffin blocks. Eleven control tissues (tonsil, stomach, prostate, pancreas, lung, kidney, skin, thyroid, spleen, adipose, liver) were also included on each block. Cores were sealed into recipient blocks by heating at 40 °C for ~40mins. Blocks were sectioned into 1.5 μM sections and affixed to glass slides. Every ninth slide was stained with H & E to provide a reference. Additional details are available in the MTA-1 Instruction Manual (
www.beecherinstruments.com). IHC staining was completed in collaboration with the Department of Pathology & Laboratory Medicine and the Molecular Pathology Core Facility (Western University). Tissues were examined using an Aperio ScanScope® slide scanner and staining quantification was performed using the Fiji plugin for ImageJ.
Flow cytometry for cell surface expression of RTKs
Parental and resistant cells were collected by trypsinization, washed in 1x PBS and counted. Single-cell suspensions were incubated in a 5% BSA solution containing anti-AXL or TYRO3, PE-conjugated antibodies at 1:50 (R & D Biosystems) for 40mins in the dark at room temperature. Cells were passed through a cell strainer to collect single cells and were protected from light until they were quantified using a Beckman-Coulter Cytomics FC500 flow cytometer with at least 10,000 events counted per test. Histograms were used to compare intensity of staining between unstained, parental and resistant cell line samples. Median fluorescence intensity was calculated for each sample and t-tests were used to quantify differences.
RNA interference
Knockdown of AXL and TYRO3 was performed using specific pooled siRNAs purchased from Dharmacon (Cat No’s. L-003104-00-0005 and L-003183-00-0005, respectively), as described previously [
23]. Scrambled control siRNA (siCT) (Thermo Fisher Scientific; Cat No. 4390843) was also used. Knockdowns were confirmed by immunoblotting.
For drug testing, cells were seeded into 96-well dishes at 2400cells/well. Alpelisib was added the next day at 5 μM and cells were incubated for 72 h. Cell viability was then determined indirectly using the PrestoBlue® Reagent (Thermo Fisher Scientific) on a Synergy™ H4 Hybrid Reader (BioTek) with 560 nm excitation and 590 nm emission wavelengths. For each condition, alpelisib-treated cells were compared with normalized untreated cells to determine the relative effect of RNAi-mediated knockdown.
Generation of PDX-derived cell line
Using cells dissociated from first-passage xenograft tumors, we attempted to establish cell lines from the patient tumors that were used to generate the PDX models (Additional Fig.
1a). Specifically, the generation of cell lines was attempted from tumor tissues that were never treated with alpelisib nor the vehicle agent. A cell line (called PDX-C Cell Line) was successfully established from one model, PDX-C (Additional Fig.
1b). STR profiling, immunoblotting and flow cytometry for cell surface expression of EpCAM (CD326) were all completed as described previously, validating the line as a human epithelial line from the same patient as the PDX-C tumor (Additional Fig.
1c, Additional Table
2).
Statistical analysis
All analyses were performed with Prism® 7 GraphPad Software. Experimental groups were compared with controls using Student’s unpaired, two-tailed t-tests. Multiple groups were compared across a single condition using one-way ANOVA. P < 0.05 was used to define significant differences from the null hypothesis.
Discussion
In this study, we demonstrate that PI3Kα inhibition exhibits anti-tumor efficacy in HNSCC models by dampening PI3K signalling, inducing PARP cleavage and reducing the proportion of actively-proliferating cells. As targeted PI3Kα inhibition is under active clinical investigation for HNSCC patients and has been FDA-approved for breast cancer treatment already, we proceeded to evaluate the efficacy of PI3Kα inhibition over time. We show in both in vitro and in vivo assays that HNSCC escapes the anti-tumor activity of alpelisib over a period of weeks to months. This acquisition of drug resistance is associated with upregulation of the RTKs TYRO3 and AXL, and an increase in signalling through the MAPK network. While AXL has been described in various settings to function as a mediator of acquired drug resistance, the involvement of its family member TYRO3 is previously unrecognized [
12,
26,
27,
38,
39].
AXL and TYRO3 are two members of the three-membered TAM family of RTKs, which also includes MER-TK [
32]. Although none of the TAM RTKs are considered to be strong oncogenes, all three have demonstrated transforming potential and it is increasingly recognized that their overexpression contributes to resistance to both standard and targeted chemotherapies [
31,
40]. AXL is by far the best-studied TAM RTK and has an established role in supporting tumorigenesis through its positive effects on cellular survival, migration, proliferation and invasion, and in mediating acquired resistance [
31]. To date, overexpression of AXL has been implicated in resistance to imatinib (BCR-Abl, c-Kit and PDGFR inhibitor), lapatinib (HER2 inhibitor), erlotinib (EGFR inhibitor) and cetuximab (EGFR-targeting monoclonal antibody), as well as resistance to the chemotherapeutics doxorubicin, cisplatin and etoposide (VP-16) in a variety of solid tumor types and blood cancers [
26,
27,
31,
38,
39,
41,
42]. In contrast, TYRO3 overexpression has been shown to mediate taxol resistance in ovarian cancer and in general, promote progression of various cancers when overexpressed [
31,
34,
43,
44].
In our HNSCC models, upregulation of both AXL and TYRO3 total protein was detected, as was an increase in cell surface localization in alpelisib-resistant versus parental samples. The involvement of AXL and TYRO3 in resistance to PI3Kα inhibition is underscored by the fact that knockdown of either or both receptors significantly sensitized cells to alpelisib treatment.
Across a large panel of HNSCC cell lines, we did not observe a trend between protein expression of TYRO3 or AXL, and sensitivity to PI3Kα inhibition. This leads us to believe that the involvement of AXL and TYRO3 in PI3K inhibitor resistance is likely based on a relative increase in expression/surface localization or altered receptor activity, rather than a baseline expression level. At present it is not well known how expression of AXL and TYRO3 is regulated; given the emerging role of TAM RTKs in cancer and drug response however, this is an area of active research [
32,
33]. Hypoxia and HIF-1α expression has been associated with AXL expression while certain microRNAs (miRNAs) are also thought to be a mediator of TAM RTK expression [
45‐
48].
Downstream of AXL and TYRO3, numerous intracellular signalling pathways have been associated with cancer progression and drug resistance [
32,
33]. Re-activation of Akt signalling and activation of the NF-κB pathway are two such examples [
38,
39]. In the context of HNSCC specifically, PLCγ-PKC signalling downstream of AXL has been identified following PI3Kα inhibition [
12]. Our data provide evidence of MAPK pathway activation, consistent across both cell lines surveyed. Further, targeted inhibition of the downstream MAPK pathway member P90RSK, alone and in combination with alpelisib, resulted in a significant reduction in cell viability of alpelisib-resistant HNSCC cells, emphasizing the relevance of this pathway in circumventing PI3K inhibition. Our observations are in accordance with previous findings that have demonstrated RSK family members to be mediators of resistance to PI3K pathway inhibition in breast cancer, and to be capable of promoting disease progression in HNSCC specifically [
35,
36].
Other studies have reported that residual mTORC1 activity following PI3K inhibition is involved with limiting its anti-tumor efficacy [
49,
50]. The activation of MAPK signalling observed in our alpelisib-resistant HNSCC cell lines supports this finding, as the MAPK pathway intersects with the PI3K pathway at several downstream points that promote mTORC1 or S6 activity (Fig.
7a) [
51]. As well, Chandarlapaty et al. (2011) described a direct association between inhibition of PI3K/Akt signalling and upregulation of RTKs, such as HER3 and IGF-1R [
52]. The pattern of receptor upregulation/activation and intracellular signalling converging on mTORC1/S6 may be a shared feature of acquired resistance to PI3K pathway inhibition across different cancer types [
12,
52]. However, the particular mechanism and mediator(s) adopted by tumor cells are likely cancer- and/or drug-specific.
Recently, PDX models have emerged as a leading preclinical platform through which to interrogate drug efficacy, interpatient response heterogeneity and, more recently, to elucidate mechanisms of drug resistance [
18,
53,
54]. In our study, we confirmed in vitro findings of TYRO3 and AXL upregulation and MAPK pathway activation upon prolonged PI3Kα inhibition in a panel of 5 unique HNSCC PDX models treated for up to 100 days with alpelisib.
Based on our collective findings, pan-TAM inhibition emerges as a logical combinatorial or second-line treatment target alongside PI3Kα inhibition in HNSCC. While AXL inhibitors are already in active development owing to its identified role in drug resistance, our findings reveal its family member TYRO3 to be similarly relevant [
31]. The importance of TYRO3 is particularly evident through our in vivo models, where we found TYRO3 protein expression to be significantly upregulated in alpelisib-resistant PDX tissues, whereas the changes in AXL expression were less apparent. We would therefore speculate that the use of a dual AXL/TYRO3 or pan-TAM inhibitor (e.g. LDC1267) would be more effective and durable over time [
31]. To date, no-specific TYRO3 inhibitors are available. Targeting the MAPK pathway is an alternative approach, as we demonstrated with the P90RSK inhibitor BI-D1870. However, MAPK pathway inhibition has had variable efficacy to date and acquired resistance to inhibitors of the MAPK pathway has been documented, in some cases involving TAM RTKs [
55,
56]. Upstream targeting of AXL and TYRO3 therefore seems to be the most logical approach. Importantly, as AXL has been identified as a drug resistance mediator to PI3K inhibition in several cancer types, pan-TAM inhibition may be a sensible approach to preventing resistance in settings even beyond HNSCC; this is a key area for future study.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.